A monoclonal antibody against the immunodominant epitope of the ribosomal P2β  protein of Trypanosoma cruzi interacts with the human β 1‐adrenergic receptor

Monoclonal antibodies were raised against a recombinant ribosomal P2β protein of Trypanosoma cruzi. One of these reacted with the C terminus of this protein (peptide R13, EEEDDDMGFGLFD) and epitope mapping confirmed that this epitope was the same as the one defined by the serum of immunized mice, and similar to the previously described chronic Chagas' heart disease (cChHD) anti‐P epitope. Western blotting showed that the monoclonal antibody recognized the parasite ribosomal P proteins, as well as the human ribosomal P proteins. Electron microscopy showed that it stained different structures in parasite and human cells. Interestingly, surface plasmon resonance measurements indicated that the affinity for the parasite ribosomal P protein epitope (R13) was five times higher than for its human counterpart (peptide H13, EESDDDMGFGLFD). Since the human epitope contained an acidic region (EESDD) similar to the AESDE peptide recognized by cChHD patients in the second extra‐cellular loop of the human β1‐adrenergic receptor, the biological activity of the antibody was assessed on neonatal rat cardiomyocytes in culture. The monoclonal antibody had an agonist‐like effect. These results, together with the fact that the monoclonal reacted in Western blots with the different isoforms of the heart β1‐adrenergic receptor, confirm the possible pathogenic role of antibodies against the parasite ribosomal P protein based on their cross‐reaction with the human β1‐adrenergic receptor.

[1]  M. Levin,et al.  The Trypanosoma cruzi ribosomal P protein family: classification and antigenicity. , 1993, Parasitology today.

[2]  G. Wallukat,et al.  Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1- adrenergic receptor , 1995, The Journal of experimental medicine.

[3]  M. V. Van Regenmortel,et al.  Antibodies to ribosomal P proteins of Trypanosoma cruzi in Chagas disease possess functional autoreactivity with heart tissue and differ from anti-P autoantibodies in lupus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Strosberg,et al.  Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. , 1990, The Journal of clinical investigation.

[5]  J. Hoebeke,et al.  Functionally active cardiac antibodies in chronic Chagas' disease are specifically blocked by Trypanosoma cruzi antigens , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  G. Wallukat,et al.  Immunochemical and functional characterization of an agonist-like monoclonal antibody against the M2 acetylcholine receptor. , 1998, European journal of biochemistry.

[7]  M. Lisanti,et al.  Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. , 2000, The Journal of biological chemistry.

[8]  M. Levin,et al.  Immunization with recombinant Trypanosoma cruzi ribosomal P2beta protein induces changes in the electrocardiogram of immunized mice. , 1997, FEMS immunology and medical microbiology.

[9]  C. Milstein,et al.  Preparation of monoclonal antibodies: strategies and procedures. , 1981, Methods in enzymology.

[10]  N. Takekoshi,et al.  Active immunization of combined beta1-adrenoceptor and M2-muscarinic receptor peptides induces cardiac hypertrophy in rabbits. , 1999, Journal of cardiac failure.

[11]  G. Wallukat,et al.  Effects of the serum gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic beta adrenoceptor function in cultured neonatal rat heart myocytes. , 1987, Biomedica biochimica acta.

[12]  C. Milstein,et al.  [1] Preparation of monoclonal antibodies: Strategies and procedures , 1981 .

[13]  M. Rosenbaum CHAGASIC MYOCARDIOPATHY. , 1964, Progress in cardiovascular diseases.

[14]  C. Beldjord,et al.  Detection of parasite DNA in Chagas' heart disease , 1995, The Lancet.

[15]  G. Wallukat,et al.  Modulation of Cardiocyte Functional Activity by Antibodies against Trypanosoma cruzi Ribosomal P2 Protein C Terminus , 2000, Infection and Immunity.

[16]  M. V. Regenmortel,et al.  Humoral autoimmune response to ribosomal P proteins in chronic Chagas heart disease , 1991, Clinical and experimental immunology.

[17]  R. Weiss,et al.  In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas' heart disease. , 1996, American heart journal.

[18]  C. Strader,et al.  Identification of residues required for ligand binding to the beta-adrenergic receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Wallukat,et al.  Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. , 1994, Circulation.

[20]  M. Caron,et al.  Cloning of the cDNA for the human beta 1-adrenergic receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Steitz,et al.  Human acidic ribosomal phosphoproteins P0, P1, and P2: analysis of cDNA clones, in vitro synthesis, and assembly , 1987, Molecular and cellular biology.

[22]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[23]  P. Gounon,et al.  Testing the ‘+2 rule’ for lipoprotein sorting in the Escherichia coli cell envelope with a new genetic selection , 1999, Molecular microbiology.

[24]  M. B. Rosenbaum,et al.  Differential Profile and Biochemical Effects of Antiautonomic Membrane Receptor Antibodies in Ventricular Arrhythmias and Sinus Node Dysfunction , 2001, Circulation.